| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gain on sale of gold bullions | NaN | 39,537 | 98,427 | 62,469 |
| Net loss | -942,720 | -787,621 | -1,509,566 | -1,326,166 |
| Depreciation expense | 6,222 | 7,602 | 5,991 | 11,520 |
| Stock issued for services | NaN | 0 | 834,600 | NaN |
| Net change in unrealized appreciation and depreciation in gold bullions | -20,408 | -33,689 | 30,968 | -107,477 |
| Impairment of right of use asset | NaN | NaN | NaN | 0 |
| Imputed interest - related party | 18,395 | 18,803 | 20,379 | 40,093 |
| Fair value of options issued for services | 10,157 | 10,157 | 4,197 | 8,394 |
| Warrants issued/(cancelled) to consultants | -206,864 | -63,582 | -97,842 | -98,069 |
| Decrease prepaid expenses | -4,176 | 4,176 | -1,467 | -13,508 |
| (increase) in inventory | 45,240 | 0 | 22,183 | NaN |
| Decrease in operating lease right-of-use, net | -13,828 | -13,567 | -14,434 | -27,662 |
| Increase in accrued expenses and other payables - related party | 217,158 | 326,834 | 207,487 | 413,426 |
| Increase in accounts payable | 14,977 | -12,141 | -34,264 | 34,514 |
| Decrease in operating lease liabilities, current | -13,127 | -12,868 | -14,784 | -28,698 |
| Net cash used in operating activities | -529,718 | -449,487 | -461,859 | -877,624 |
| Proceeds from sale of investment in gold | NaN | 73,445 | 222,754 | 147,238 |
| Purchase of fixed assets | 14,116 | 1,612 | 0 | 3,783 |
| Net cash provided by investing activities | -14,116 | 71,833 | 222,754 | 143,455 |
| Principal payments on debt - related party | NaN | 75,000 | 50,000 | 0 |
| Payment of debt offering costs | NaN | 0 | 0 | 10,000 |
| Proceeds from standby equity purchase agreement | 1,644,588 | 677,198 | 1,069,335 | 856,367 |
| Net cash provided by financing activities | 1,644,588 | 602,198 | 1,019,335 | 846,367 |
| Net change in cash and cash equivalents | 1,100,754 | 224,544 | 780,230 | 112,198 |
| Cash and cash equivalents at beginning of period | 1,790,236 | 1,565,692 | 673,264 | NaN |
| Cash and cash equivalents at end of period | 2,890,990 | 1,790,236 | 1,565,692 | NaN |
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)